Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03582761
Other study ID # JSVCT048
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date May 1, 2019
Est. completion date May 1, 2020

Study information

Verified date May 2019
Source Jiangsu Province Centers for Disease Control and Prevention
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a multicenter, case-control phase IV clinical trial to evaluate the effectiveness of the EV71 vaccine. About 40000 children in the town aged 6-35 months will be recruited and vaccinated with EV71 vaccines, which account for 20-40% of the children aged 6-35 months in the areas. The subjects will be vaccinated with EV71 vaccine at day 0 and day 28. Other children of appropriate age in the town will choose voluntarily whether or not to be vaccinated with EV71 vaccine. All children's vaccination of EV71 vaccines will be recorded in the study areas and the coverage rate of EV71 vaccine in the town will be calculated. The vaccination is expected to complete before the epidemic peak of HFMD. Surveillance of HFMD cases caused by EV71 will be conducted in hospitals of the study areas for 10-12 months, which cover a whole HFMD epidemic period. Throat and anal swabs will be collected from children with a clinically diagnosed HFMD for typing of human enteroviruses tested by PCR. The HFMD cases with EV71 positive will be recruited as cases, while those with EV71 negative will be recruited as test-negative controls. Besides, for each EV71-associated HFMD cases, the investigators will select 4 community controls mateced with each case for age, sex and residence.


Recruitment information / eligibility

Status Completed
Enrollment 40000
Est. completion date May 1, 2020
Est. primary completion date May 1, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 6 Months to 35 Months
Eligibility Inclusion Criteria: For vaccination group: - Healthy children aged 6-35 months - Subjects who have been clinically judged to be healthy by the researcher after being asked about the medical history and related physical examination - The subjects' guardians agree the requirements of the protocol and the relevant follow up visits - The subjects' guardians agree and sign the informed consent For case group: - Aged from 6 to 47 months - Clinical diagnosis of HFMD - At least one throat swab or anal swab detected EV71 positive by PCR - The subjects' guardians agree and sign the informed consent For hospital control group: - Aged from 6 to 47 months - Clinical diagnosis of HFMD - Throat swabs or anal swabs are positive for enterovirus and negative for EV71 - The subjects' guardians agree and sign the informed consent For community control group: - Aged from 6 to 47 months - No clinically diagnosed HFMDs, and no fever, HFMD suspected symptoms, such as hand, foot and mouth herpes - The same gender as the matched case - The age is similar to that of matched case (for cases = 12 months of age, the age difference is within ±3 months, for case < 12 months of age, the age difference is within ±30 days) - Near the residence of the case (the same village or adjacent village) - The subjects' guardians agree and sign the informed consent Exclusion Criteria: For vaccination group: - Subject who has a medical history of HFMD caused by EV71 or has been vaccinated with EV71 vaccine - Subject who is known to be allegric to the componets of the vaccine - Subject with fever or acute diseases or at acute stage of chronic diseases - Subject with severe chronic diseases and allergies - Subject with thrombocytopenia or hemorrhagic diseases - Subject who is receiving immunosuppressive therapy or with immunodeficiency - Subject with uncontrolled epilepsy and other progressive neurological illness, such as Guillain-Barre syndrome. Exclusion Criteria for the second dose: - Have severe allergic reaction after first dose - Have severe adverse reactions related to first dose - Any situation meet the exclusion criteria stated in the exclusion criteria for first dose - Acute infection or illness - Other factors that are not suitable for clinical trials according to the judgment of researchers For case group: - Unknown of EV71 vaccination history - EV71 related disease occurred within 28 days after the first vaccination - The place of residence is not included in the study areas For hospital control group: - Unknown of EV71 vaccination history - A history of HFMD caused by EV71 or unknown HFMD related pathogen - The place of residence is not included in the study areas - For community control group: - For community control group: For community control group: - Unknown of EV71 vaccination history - A history of HFMD caused by EV71 or unknown HFMD related pathogen

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
EV71 vaccine
EV71 vaccine of 320U /0.5ml will be given to 40000 children aged 6-35 months old on day0,28

Locations

Country Name City State
China Jiangsu Provincial Center for Diseases Control and Prevention Nanjing Jiangsu
China Hubei Provincial Center for Diseases Control and Prevention Wuhan Hubei

Sponsors (3)

Lead Sponsor Collaborator
Jiangsu Province Centers for Disease Control and Prevention Hubei Provincial Center for Disease Control and Prevention, Wuhan Institute of Biological Products Co., Ltd

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Odds ratio (OR) of the immunization of EV-A71 vaccine in cases vs control groups Cases are defined as eligible patients who tested positive for enteroviruse 71. For each case, we will select two groups of control children, including hospital test-negative control and community control. Logistic regression is performed to calculate the odds ratio (OR) of vaccination in cases vs each of the control groups. within 12 months after completion of vaccination
Secondary Incidence and severity of adverse reactions/adverse events in children aged 6-35 months after EV71 vaccine receiving. Incidence and severity of adverse reactions/adverse events in children aged 6-35 months within 1 month after completion of vaccination. 1 month after completion of vaccination
See also
  Status Clinical Trial Phase
Recruiting NCT06063057 - Inactivated Bivalent Enterovirus Vaccine (Vero Cell) Phase I/II Clinical Trial Phase 1/Phase 2
Completed NCT04133584 - The Immunogenicity and Safety of the Vaccination of Inactivated Enterovirus 71 Vaccine and Seasonal Influenza Vaccine Phase 4
Completed NCT03241030 - Sucralfate to Improve Oral Intake in Children With Infectious Oral Ulcers: a Randomized, Double-blind, Placebo-Controlled Trial Phase 2
Completed NCT01255124 - Study on Dynamic Changes of the Maternal Anti-EV71 and Anti-CVA16 Antibody Levels in Infants and Young Children N/A
Completed NCT03873740 - Immunogenicity and Safety of Two Different Commercial EV71 Vaccines Phase 4
Completed NCT05637229 - A Serosurvey Study of Hand, Foot, and Mouth Disease in Indonesia
Recruiting NCT06146088 - Lot-to-lot Consistency Study of Three Commercial Batches of Enterovirus 71 Vaccine Phase 4
Active, not recruiting NCT06209398 - Immunogenicity of the Inactivated EV71 Vaccine Combined With Hepatitis B and Group A Meningococcal Vaccine Phase 4
Recruiting NCT01175915 - A Clinical Trial To Evaluate Reduning Injection in the Treatment of Mild Type of Hand, Foot, and Mouth Disease N/A
Recruiting NCT01145664 - A Multi-Center Clinical Trial To Evaluate Chinese Herbal Medicines in the Treatment of Severe Hand-foot-mouth Disease N/A
Completed NCT01182532 - A Clinical Trial to Evaluate the Effectiveness and Safety of Chinese Medicine in the Treatment of Mild Type of Hand, Foot, and Mouth Disease N/A
Completed NCT03281174 - Five-year Immune Persistence Study of Inactivated Enterovirus Type 71 (EV71) Vaccine N/A
Completed NCT03903926 - Efficacy Trial of a Commercial EV71 Vaccine Phase 4
Completed NCT02001233 - A Follow-up Study for a Phase III, Efficacy Trial in Inactivated Enterovirus Type 71 (EV71) Vaccine
Completed NCT03909074 - Clinical Trial of Enterovirus 71(EV71) Inactivated Vaccine in Children Aged 36-71 Months Phase 3
Completed NCT01769794 - Chinese Medicinal Treatment on Mild Hand, Foot, and Mouth Disease: Multicenter, Prospective, Randomized Double-blind, Placebo-controlled Study N/A
Recruiting NCT01182025 - A Clinical Trial to Evaluate the Effectiveness and Safety of Xiyanping Injection in the Treatment of Mild Type of Hand, Foot, and Mouth Disease N/A
Recruiting NCT06263439 - Surveillance of HFMD in Pediatric Outpatients
Not yet recruiting NCT05397587 - An Immunity Persistence Study of Enterovirus 71 Inactivated Vaccine (Vero Cell) Phase 4
Completed NCT04111432 - Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Expanded Programme on Immunization Vaccines Phase 4